Growth hormone secretagogue

CJC-1295 (no DAC) + Ipamorelin blend

The classic growth-hormone stack in one vial: a GHRH fragment with a secretagogue, unapproved and prohibited in sport.

Anecdotal evidenceNot approvedAdd to compare

What it is

A prepackaged mixture of mod GRF 1-29 — the short-acting GHRH analogue — and ipamorelin, usually 5 mg of each. The pairing is popular because the two act on different receptors in the same growth-hormone pathway. Neither is an approved medicine, the combination has not been tested in a controlled human trial, and both are prohibited in sport.

How it works

1
The GHRH fragment binds pituitary GHRH receptors, priming growth-hormone release.
2
Ipamorelin acts on the ghrelin receptor, GHS-R1a, to trigger the release itself.
3
Together they are said to produce a larger pulse than either alone — shown in growth-hormone testing, but never linked to a proven body-composition or recovery outcome.
4
Both are short-acting, so a dose produces a brief pulse rather than sustained elevation.
5
IGF-1 rises secondarily with repeated use.

What it's studied for

Growth-hormone secretion and pulsatility research

Body-composition and recovery claims, without trials

Sleep and 'anti-ageing' claims, anecdote only

Diagnostic growth-hormone stimulation testing for the GHRH component

Reported and studied effects

A measurable growth-hormone pulse after dosing
Modest IGF-1 increase with repeated use
Reported improved sleep and recovery from user accounts
Fluid retention and joint stiffness, as with the growth-hormone class

Research protocol notes

Research context only

Research context only — no approved protocol exists. Community schedules use roughly 200 micrograms of each peptide once or twice daily, cycling 8–12 weeks on with 2–4 weeks off; 12 syringe units from a 3 ml reconstitution is a common vendor figure. None of this has been evaluated in a trial, and units depend on the exact concentrations in the vial.

These figures are described so you can understand what researchers did. They are not a dose, a schedule, or a suggestion — and they are not a substitute for a doctor.

Possible side effects and contraindications

Safety profile

Possible side effects

Headache, flushing and dizziness
Water retention and joint aches
Tingling or numbness in the hands
Increased appetite
Unknown long-term effects of chronic IGF-1 elevation

Contraindications and cautions

Cancer history or active malignancy
Diabetes or impaired glucose tolerance
Pregnancy, breastfeeding and childhood
Prohibited in competitive sport

A side-effect list is never complete, and these are not the only situations that warrant caution. Anything unexpected, or anything you are unsure about, should be discussed with a doctor before use.

Evidence assessment

Anecdotal evidenceNo controlled human data

No controlled human data

Small studies document growth-hormone release from the individual peptides, but no trial has examined the blend or any of the outcomes it is sold for.

References

References link to published literature, regulator pages or literature indexes. Where a link points to a search, it collects the peer-reviewed work on that molecule rather than a single study.

Compare CJC-1295 (no DAC) + Ipamorelin blend with another peptide →

Related peptides

Other entries in Growth hormone secretagogue.

All Growth hormone secretagogue peptides →

Growth hormone secretagogue

CJC-1295

A modified growth-hormone-releasing hormone analogue whose albumin binding gives it an unusually long action. Studied in small human trials; not an approved medicine.

Limited evidenceNot approved

Growth hormone secretagogue

CJC-1295 (no DAC) / mod GRF 1-29

The short-acting sister of CJC-1295: a GHRH fragment that produces brief growth-hormone pulses instead of sustained elevation.

Limited evidenceNot approved

Growth hormone secretagogue

GHRP-2 (pralmorelin)

A potent ghrelin-receptor secretagogue used in some countries as a growth-hormone test; sold unapproved for body composition.

Limited evidenceInvestigational